Diagnostic Utility of Exome Sequencing for Kidney Disease

Emily Groopman(MACOM (United States)), Maddalena Marasà(MACOM (United States)), Sophia Cameron‐Christie(MACOM (United States)), Slavé Petrovski(MACOM (United States)), Vimla S. Aggarwal(MACOM (United States)), Hila Milo Rasouly(MACOM (United States)), Yifu Li(MACOM (United States)), Junying Zhang(MACOM (United States)), Jordan G. Nestor(MACOM (United States)), Priya Krithivasan(MACOM (United States)), Wan Yee Lam(MACOM (United States)), Adele Mitrotti(MACOM (United States)), Stacy Piva(MACOM (United States)), Byum Hee Kil(MACOM (United States)), Debanjana Chatterjee(MACOM (United States)), Rachel Reingold(MACOM (United States)), Drew Bradbury(MACOM (United States)), Michael DiVecchia(MACOM (United States)), Holly Snyder(MACOM (United States)), Xueru Mu(MACOM (United States)), Karla Mehl(MACOM (United States)), Olivia Balderes(MACOM (United States)), David Fasel(MACOM (United States)), Chunhua Weng(MACOM (United States)), Jai Radhakrishnan(MACOM (United States)), Pietro A. Canetta(MACOM (United States)), Gerald B. Appel(MACOM (United States)), Andrew S. Bomback(MACOM (United States)), Wooin Ahn(MACOM (United States)), Natalie Uy(MACOM (United States)), Shumyle Alam(MACOM (United States)), David J. Cohen(MACOM (United States)), Russell J. Crew(MACOM (United States)), Geoffrey K. Dube(MACOM (United States)), Maya K. Rao(MACOM (United States)), Sitharthan Kamalakaran(MACOM (United States)), Brett Copeland(MACOM (United States)), Zhong Ren(MACOM (United States)), Joshua Bridgers(MACOM (United States)), Colin D. Malone(MACOM (United States)), Caroline M. Mebane(MACOM (United States)), Neha Dagaonkar(MACOM (United States)), Bengt Fellström(MACOM (United States)), Carolina Haefliger(MACOM (United States)), Sumit Mohan(MACOM (United States)), Simone Sanna‐Cherchi(MACOM (United States)), Krzysztof Kiryluk(MACOM (United States)), Jan Fleckner(MACOM (United States)), Ruth March(MACOM (United States)), Adam Platt(MACOM (United States)), David B. Goldstein(MACOM (United States)), Ali G. Gharavi(MACOM (United States))
New England Journal of Medicine
December 26, 2018
Cited by 764Open Access
Full Text

Abstract

BACKGROUND: Exome sequencing is emerging as a first-line diagnostic method in some clinical disciplines, but its usefulness has yet to be examined for most constitutional disorders in adults, including chronic kidney disease, which affects more than 1 in 10 persons globally. METHODS: We conducted exome sequencing and diagnostic analysis in two cohorts totaling 3315 patients with chronic kidney disease. We assessed the diagnostic yield and, among the patients for whom detailed clinical data were available, the clinical implications of diagnostic and other medically relevant findings. RESULTS: In all, 3037 patients (91.6%) were over 21 years of age, and 1179 (35.6%) were of self-identified non-European ancestry. We detected diagnostic variants in 307 of the 3315 patients (9.3%), encompassing 66 different monogenic disorders. Of the disorders detected, 39 (59%) were found in only a single patient. Diagnostic variants were detected across all clinically defined categories, including congenital or cystic renal disease (127 of 531 patients [23.9%]) and nephropathy of unknown origin (48 of 281 patients [17.1%]). Of the 2187 patients assessed, 34 (1.6%) had genetic findings for medically actionable disorders that, although unrelated to their nephropathy, would also lead to subspecialty referral and inform renal management. CONCLUSIONS: Exome sequencing in a combined cohort of more than 3000 patients with chronic kidney disease yielded a genetic diagnosis in just under 10% of cases. (Funded by the National Institutes of Health and others.).


Related Papers